Cellivate Technologies is developing cutting-edge solutions for biomanufacturing and cell culture, including a novel cell-based serum intended to replace fetal bovine serum and sophisticated microcarriers to accelerate cell growth. The company says its products could lower costs, boost productivity, and address ethical concerns associated with traditional cell culture methods. Cellivate plans to use newly raised funds to quicken research and development, increase production of its products, and broaden its customer base. The company cites market research projecting the cell culture market to reach $33 billion by 2030, with particular focus on microcarriers and serum. Cellivate was founded by Viknish Krishnan Kutty and presents its offerings as ways to reduce reliance on animal slaughter by enabling cells to produce goods and ingredients traditionally derived from animals.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2024